Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526)
02/2003
02/11/2003US6518015 Peptide comprising the sequence CAFRQVC and methods using it
02/11/2003US6518013 Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission
02/11/2003US6518011 Monitoring the processing of epitope-tagged beta-APP. More specifically, the present invention relates to the use of such methods and composition for monitoring responses of cells expressing such epitope-tagged beta-APP or segments of cell
02/11/2003US6517843 Recombinant immunogen comprised of an inactivated porcine circovirus-2
02/11/2003US6517842 Marburg virus vaccines
02/11/2003US6517839 Immune response to intracellular pathogens or interferon gamma-sensitive tumors; Mycobacterium tuberculosis;lipopeptide N-terminal ester- or amide-linked fatty acyl group, Xaa-Ser-Ser-Asn-Lys-Ser; Xaa is an N-acyldiacylglycerolcysteine
02/11/2003US6517838 Protecting against infection with Borrelia burgdorferi, Lyme disease
02/11/2003US6517837 Isolated nucleic acid molecules associated with colon cancer and methods for diagnosing and treating colon cancer
02/11/2003US6517835 Growth differentiation factor-11
02/11/2003US6517830 In vivo gene delivery of nucleic acid sequences encoding the factor VIII protein to the liver endothelial sinusoidal cells; use in the gene therapy treatment of hemophilia A
02/11/2003US6517828 C-CAM as an angiogenesis inhibitor
02/11/2003US6517203 System, apparatus, and method for correcting vision using electro-active spectacles
02/11/2003CA2216851C Radiolabeled peptides for diagnosis and therapy
02/11/2003CA2174529C Dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5) and uses thereof
02/11/2003CA2170509C Dna encoding prostaglandin receptor ep2
02/11/2003CA2162880C Composite synthetic peptide construct eliciting neutralizing antibodies and cytotoxic t lymphocytes against hiv
02/11/2003CA2152667C Bone resorption assay
02/11/2003CA2151564C Monomeric insulin analog formulations
02/11/2003CA2142181C Androgen regulation with dna sequences of rat probasin gene
02/11/2003CA2141554C Morphogen-induced nerve regeneration and repair
02/11/2003CA2139645C Immunoassays for anti-hcv antibodies using antigens with conformational epitopes
02/11/2003CA2133843C Melanocyte stimulating hormone receptor and uses
02/11/2003CA2102606C Compositions for the treatment of chronic fatigue syndrome
02/11/2003CA2078689C Chimeric antibodies with receptor binding ligands in place of their constant region
02/11/2003CA2068871C Non-glycosylated fgf-4 and compositions containing the same
02/11/2003CA2036657C Temporary minimal protection synthesis of lh-rh analogs
02/11/2003CA2005704C Pneumolysin mutants and pneumococcal vaccines made therefrom
02/08/2003CA2396616A1 Modified cdna for high expression levels of factor viii and its derivatives
02/06/2003WO2003010329A2 Nucleic acid-associated proteins
02/06/2003WO2003010327A2 Novel proteins and nucleic acids encoding same
02/06/2003WO2003010321A1 Recombinant vectors derived from adeno-associated virus expressing tam67 for gene therapy
02/06/2003WO2003010320A2 Recombinant vector derived from adeno-associated virus for gene therapy
02/06/2003WO2003010317A1 Novel peptides of the respiratory syncytial virus (rsv) g protein and their use in a vaccine
02/06/2003WO2003010315A1 Abca7 splicing variant
02/06/2003WO2003010314A2 Gmg-2 polynucleotides and polypeptides and uses thereof
02/06/2003WO2003010313A1 Novel diphtheria anatoxins and their use as carrier
02/06/2003WO2003010310A1 Method of examining allergic disease
02/06/2003WO2003010306A1 Viral mutants that selectively replicate in targeted human cancer cells
02/06/2003WO2003010293A2 Maize basal layer antimicrobial protein polynucleotides and methods of use
02/06/2003WO2003010291A2 Treatment of immune disorders and b cell disorders
02/06/2003WO2003010290A2 Novel class ii cytokine receptors and uses thereof
02/06/2003WO2003010288A2 Yeast expression systems, methods of producing polypeptides in yeast, and compositions relating to same
02/06/2003WO2003010286A2 Nucleic acids, polypeptides, and methods for modulating apoptosis
02/06/2003WO2003010205A1 Genes induced by hypoxia
02/06/2003WO2003010204A1 Process for preparation of polypeptides of interest from fusion peolypeptides
02/06/2003WO2003010202A1 Concatameric immunoadhesion
02/06/2003WO2003010201A2 Blood group antigen fusion polypeptides and methods of use thereof
02/06/2003WO2003010200A2 Nucleic acid encoding polypeptide involved in cellular entrance of the prrs virus
02/06/2003WO2003010199A2 Identification of specific tumour antigens by means of the selection of cdna libraries with sera and the use of said antigens in diagnostic imaging techniques
02/06/2003WO2003010198A1 Identification of specific tumour antigens by selection of cdna libraries with sera and use of said antigens in diagnostic techniques
02/06/2003WO2003010197A2 Gmg-1 polynucleotides and polypeptides and uses thereof
02/06/2003WO2003010196A2 Variants and exons of the glyt1 transporter
02/06/2003WO2003010195A2 Novel compounds
02/06/2003WO2003010194A2 Meningococcus adhesins nada, app and orf 40
02/06/2003WO2003010192A2 An inducer of apoptosis
02/06/2003WO2003010191A1 New cationic peptides of the dermaseptin family isolated from the skin secretion of phyllomedusa hypochondrialis
02/06/2003WO2003010190A2 Peptide screen
02/06/2003WO2003010188A1 Production of high molecular mass lectins
02/06/2003WO2003010186A2 Method for making acylated polypeptides
02/06/2003WO2003010185A2 Method for making acylated polypeptides
02/06/2003WO2003010176A2 Protein-nucleic acid complexes
02/06/2003WO2003009867A1 Use of biologically active hiv-1 tat, fragments or derivates thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases
02/06/2003WO2003009866A1 Use of the disintegrin domain of an adamalysin as anti-angiogenic, anti-invasive and anti-metastatic agent
02/06/2003WO2003009858A1 Fermentation medium and method
02/06/2003WO2003009815A2 Compositions and methods for modulating blood-brain barrier transport
02/06/2003WO2003009814A2 Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
02/06/2003WO2003009812A2 Use of glycosylceramides as adjuvants for vaccines against infections and cancer
02/06/2003WO2003009804A2 Conformationally constrained parathyroid hormone (pth) analogs
02/06/2003WO2002097134A3 Modified peptide nucleic acid
02/06/2003WO2002093177A3 Assays for identifying modulators of rhomboid polypeptides
02/06/2003WO2002092627A3 Use of casb 7439 for treatment and diagnosis of lung cancer
02/06/2003WO2002083895A3 New gene from crassostera gigas
02/06/2003WO2002083722A3 Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides
02/06/2003WO2002081730A3 Trac1: modulators of lymphocyte activation
02/06/2003WO2002079245A3 Method for improving plant tolerance to environmental stress
02/06/2003WO2002077160A3 Methods of making and uses of compositions that modulate intronic region-encoded protein function
02/06/2003WO2002069689A3 Gssp4 polynucleotides and polypeptides and uses thereof
02/06/2003WO2002068467A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
02/06/2003WO2002066610A3 Hepp, a novel gene with a role in hematopoietic and neural development
02/06/2003WO2002063005A3 Lipid-associated molecules
02/06/2003WO2002063002A3 Novel human transporter protein and polynucleotides encoding the same
02/06/2003WO2002062848A3 Regulation of cc chemokine receptor 3 (ccr3) expression
02/06/2003WO2002062837A3 Cells with enhanced pkr expression for increasing cytokine production
02/06/2003WO2002060950A3 Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
02/06/2003WO2002059613A3 Oomycete ftsz-mt as a target for antimicrobial-specific biocides
02/06/2003WO2002057308A3 Zinc finger polypeptides and their use
02/06/2003WO2002040545A9 Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the fv to lower the isoelectric point
02/06/2003WO2002032925A9 Protein scaffolds for antibody mimics and other binding proteins
02/06/2003WO2002028900A9 Tach: new tnf-receptor family nucleic acids and polypeptides
02/06/2003WO2002027007A3 Production of viral vectors
02/06/2003WO2002027005A9 Enhanced transfection system
02/06/2003WO2002024879A3 Glutaryl cephalosporin amidase from pseudomonas diminuta bs-203
02/06/2003WO2002022651A3 Haplotypes of the ccr8 gene
02/06/2003WO2002021996A3 Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
02/06/2003WO2002020722A3 Methods and compositions for in vitro targeting
02/06/2003WO2002019963A3 Synthetic erythropoiesis stimulating proteins
02/06/2003WO2002018601A3 Essential bacteria genes and genome scanning in haemophilus influenzae for the identification of 'essential genes'
02/06/2003WO2002018577A3 48921, a novel human gtp releasing factor and uses therefor
02/06/2003WO2002018414A3 Haplotypes of the bf gene
02/06/2003WO2002016633A3 Methods for identifying inhibitors of ubiquitin-mediated proteolysis of ikb
1 ... 1670 1671 1672 1673 1674 1675 1676 1677 1678 1679 1680 1681 1682 1683 1684 1685 1686 1687 1688 1689 1690 ... 2916